Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. Hpn 100
2. Hpn-100
3. Hpn100
4. Ravicti
1. 611168-24-2
2. Ravicti
3. Hpn-100
4. Glycerolphenylbutyrate
5. Gt4p
6. Hpn100
7. Propane-1,2,3-triyl Tris(4-phenylbutanoate)
8. Zh6f1vcv7b
9. Glycerol Phenylbutyrate [usan]
10. Glycerol Phenylbutyrate (usan)
11. Benzenebutanoic Acid, 1,1',1''-(1,2,3-propanetriyl) Ester
12. Unii-zh6f1vcv7b
13. Tris(4-phenylbutyryl)glycerol
14. Glyceryl Tri-4-phenylbutyrate
15. Glyceryl Tri-(4-phenylbutyrate)
16. Hpn 100
17. Glycerol Phenylbutyrate [usan:inn]
18. Ravicti (tn)
19. Glycerol-phenylbutyrate
20. 2,3-bis(4-phenylbutanoyloxy)propyl 4-phenylbutanoate
21. Chembl2105745
22. Schembl10102804
23. Dtxsid40210005
24. Hpn-100hpn-100
25. Chebi:134745
26. Hy-b2087
27. Glycerol Phenylbutyrate [mi]
28. Tri(4-phenylbutyryl)glycerol
29. Glycerol Phenylbutyrate [inn]
30. S6981
31. Glyceryl Tri(4-phenylbutyrate)
32. At33615
33. Db08909
34. Glycerol Phenylbutyrate [vandf]
35. Glycerol Phenylbutyrate [who-dd]
36. Glyceryl Tri (4-phenylbutyrate)
37. Cs-0017499
38. Glycerol Phenylbutyrate [orange Book]
39. D10127
40. Q15322709
41. Benzenebutanoic Acid, 1,2,3-propanetriyl Ester
Molecular Weight | 530.6 g/mol |
---|---|
Molecular Formula | C33H38O6 |
XLogP3 | 6.7 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 20 |
Exact Mass | 530.26683893 g/mol |
Monoisotopic Mass | 530.26683893 g/mol |
Topological Polar Surface Area | 78.9 Ų |
Heavy Atom Count | 39 |
Formal Charge | 0 |
Complexity | 648 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Ravicti |
PubMed Health | Glycerol Phenylbutyrate (By mouth) |
Drug Classes | Hyperammonemia Agent |
Drug Label | RAVICTI (glycerol phenylbutyrate) is a clear, colorless to pale yellow oral liquid. It is insoluble in water and most organic solvents, and it is soluble in dimethylsulfoxide (DMSO) and >65% acetonitrile.Glycerol phenylbutyrate is a nitrogen-binding... |
Active Ingredient | Glycerol phenylbutyrate |
Dosage Form | Liquid |
Route | Oral |
Strength | 1.1gm/ml |
Market Status | Prescription |
Company | Hyperion Therap |
2 of 2 | |
---|---|
Drug Name | Ravicti |
PubMed Health | Glycerol Phenylbutyrate (By mouth) |
Drug Classes | Hyperammonemia Agent |
Drug Label | RAVICTI (glycerol phenylbutyrate) is a clear, colorless to pale yellow oral liquid. It is insoluble in water and most organic solvents, and it is soluble in dimethylsulfoxide (DMSO) and >65% acetonitrile.Glycerol phenylbutyrate is a nitrogen-binding... |
Active Ingredient | Glycerol phenylbutyrate |
Dosage Form | Liquid |
Route | Oral |
Strength | 1.1gm/ml |
Market Status | Prescription |
Company | Hyperion Therap |
Glycerol phenylbutyrate is a nitrogen-binding agent for the chronic management of adult and pediatric patients 2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
FDA Label
Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e. g. , essential amino acids, arginine, citrulline, protein-free calorie supplements).
Glycerol phenylbutyrate prolongs the QTc interval.
A16AX09
A - Alimentary tract and metabolism
A16 - Other alimentary tract and metabolism products
A16A - Other alimentary tract and metabolism products
A16AX - Various alimentary tract and metabolism products
A16AX09 - Glycerol phenylbutyrate
Absorption
Glycerol phenylbutyrate is a prodrug in which phenylbutyrate (PBA) is released from the glycerol backbone by lipases in the gastrointestinal tract. PBA then undergoes beta-oxidtion to form PAA. When a single oral dose of 2.9 mL/m2 of Glycerol phenylbutyrate is given to fasting adult subjects, the pharmacokinetic parameters are as follows: Tmax: PBA = 2 hours; PAA = 4 hours; PAGN = 4 hours. Cmax: PBA = 37.0 g/mL; PAA = 14.9 g/mL; PAGN = 30.2 g/mL. In healthy subjects, the hydrolysis of glycerol phenylbutyrate is incomplete, but to what extent is unknown. When glycerol phenylbutyrate is given to adult UCD patients, maximum plasma concentrations at steady state (Cmaxss) of PBA, PAA, and PAGN occurred at 8 h, 12 h, and 10 h, respectively, after the first dose in the day. Intact glycerol phenylbutyrate was not detectable in plasma in UCD patients.
Route of Elimination
Glycerol phenylbutyrate is mainly excreted as PAGN in the urine (68.9% in adults and 66.5% in pediatric UCD patients). PAA and PBA represented minor urinary metabolites, each accounting for <1% of the administered dose of PBA.
Pancreatic lipases hydrolyze glycerol phenylbutyrate to release PBA from the glycerol backbone. PBA undergoes -oxidation to PAA, which is conjugated with glutamine in the liver and in the kidney through the enzyme phenylacetyl-CoA: L-glutamine-N-acetyltransferase to form PAGN.
The toxic accumulation of ammonia in the blood and brain arise from urea cycle disorders in which patients are deficient in critical enzymes or transporters that are involved in the synthesis of urea from ammonia. Glycerol phenylbutyrate is a prodrug - the major metabolite, phenylacetate (PAA) is the molecule that binds to nitrogen. PAA conjugates with glutamine (which contains 2 molecules of nitrogen) via acetylation in the liver and kidneys to form phenylacetylglutamine (PAGN), which is excreted by the kidneys. PAGN, like urea, contains 2 moles of nitrogen and provides an alternate vehicle for waste nitrogen excretion.
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
GDUFA
DMF Review : Complete
Rev. Date : 2013-09-16
Pay. Date : 2013-07-02
DMF Number : 27125
Submission : 2013-07-03
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-11-15
Pay. Date : 2024-08-29
DMF Number : 40388
Submission : 2024-09-18
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-05-13
Pay. Date : 2020-02-26
DMF Number : 34468
Submission : 2020-04-21
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-12
Pay. Date : 2014-06-12
DMF Number : 28298
Submission : 2014-06-11
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-01-22
Pay. Date : 2024-01-04
DMF Number : 34618
Submission : 2020-02-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-08-08
Pay. Date : 2022-05-24
DMF Number : 37042
Submission : 2022-06-27
Status : Active
Type : II
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
About the Company : Established in 2012, Nuray Chemicals Pvt Ltd is an API manufacturer for highly regulated markets. Its manufacturing facility with state-of-the-art R&D is located near Chennai in th...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : SMS Lifesciences is a global player in APIs/Intermediates manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off a...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2030-09-22
US Patent Number : 10668040
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 10183002
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 9326966
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 10045958
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 9999608
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 10183003
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 10183006
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 9561197
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1383
Delist Requested :
Patent Use Description : DOSAGE ADJUSTMENT OF A...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 10183005
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
Patent Expiration Date : 2030-09-22
US Patent Number : 9962359
Drug Substance Claim :
Drug Product Claim :
Application Number : 203284
Patent Use Code : U-1816
Delist Requested :
Patent Use Description : TREATMENT OF A UREA CY...
Patent Expiration Date : 2030-09-22
ABOUT THIS PAGE
A Glycerol Phenylbutyrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Glycerol Phenylbutyrate, including repackagers and relabelers. The FDA regulates Glycerol Phenylbutyrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Glycerol Phenylbutyrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Glycerol Phenylbutyrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Glycerol Phenylbutyrate supplier is an individual or a company that provides Glycerol Phenylbutyrate active pharmaceutical ingredient (API) or Glycerol Phenylbutyrate finished formulations upon request. The Glycerol Phenylbutyrate suppliers may include Glycerol Phenylbutyrate API manufacturers, exporters, distributors and traders.
click here to find a list of Glycerol Phenylbutyrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Glycerol Phenylbutyrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Glycerol Phenylbutyrate active pharmaceutical ingredient (API) in detail. Different forms of Glycerol Phenylbutyrate DMFs exist exist since differing nations have different regulations, such as Glycerol Phenylbutyrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Glycerol Phenylbutyrate DMF submitted to regulatory agencies in the US is known as a USDMF. Glycerol Phenylbutyrate USDMF includes data on Glycerol Phenylbutyrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Glycerol Phenylbutyrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Glycerol Phenylbutyrate suppliers with USDMF on PharmaCompass.
A Glycerol Phenylbutyrate written confirmation (Glycerol Phenylbutyrate WC) is an official document issued by a regulatory agency to a Glycerol Phenylbutyrate manufacturer, verifying that the manufacturing facility of a Glycerol Phenylbutyrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Glycerol Phenylbutyrate APIs or Glycerol Phenylbutyrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Glycerol Phenylbutyrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Glycerol Phenylbutyrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Glycerol Phenylbutyrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Glycerol Phenylbutyrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Glycerol Phenylbutyrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Glycerol Phenylbutyrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Glycerol Phenylbutyrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Glycerol Phenylbutyrate suppliers with NDC on PharmaCompass.
Glycerol Phenylbutyrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Glycerol Phenylbutyrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Glycerol Phenylbutyrate GMP manufacturer or Glycerol Phenylbutyrate GMP API supplier for your needs.
A Glycerol Phenylbutyrate CoA (Certificate of Analysis) is a formal document that attests to Glycerol Phenylbutyrate's compliance with Glycerol Phenylbutyrate specifications and serves as a tool for batch-level quality control.
Glycerol Phenylbutyrate CoA mostly includes findings from lab analyses of a specific batch. For each Glycerol Phenylbutyrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Glycerol Phenylbutyrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Glycerol Phenylbutyrate EP), Glycerol Phenylbutyrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Glycerol Phenylbutyrate USP).
LOOKING FOR A SUPPLIER?